GuidelineGut2020
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.
2 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
In one paragraph
Guideline in Gut, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT04759001 phase1 / phase2recruitingnot on this mapstarted 2021, after this paper: background citation
Faecal Microbiota Transplantation to Eradicate Gut Colonisation From Carbapenem-resistant Enterobacteriaceae: a Randomised Controlled Trial
Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Changes in the gut microbiota of patients with sarcopenia based on 16S rRNA gene sequencing: a systematic review and meta-analysis.Frontiers in nutrition · 2024Pooled it
- Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.Nature medicine · 2026Trial
- Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety.Nature communications · 2023Trial
- Trial
- Immunomodulatory Role of Milk on Gut Microbiota: Implications for Enhancing Oral Vaccine Efficacy.Probiotics and antimicrobial proteins · 2026Review
- Enhanced formulation of precision probiotics through active machine learning.Biology methods & protocols · 2026Article
- Fecal microbiota transplantation: from empirical remedy to precision medicine.Frontiers in microbiomes · 2026Review
- Article
- Crosstalk Among Gut Microbiota, Microbial Metabolites, and Inflammatory Cytokines: Current Understanding and Future Directions.Foods (Basel, Switzerland) · 2025Review
- Exploring the oncogenic potential of SARS-CoV-2 in the gastrointestinal tract.World journal of gastroenterology · 2025Review
- Temporal dynamics of SARS-CoV-2 shedding in feces and saliva: a longitudinal study in Norfolk, United Kingdom during the 2021-2022 COVID-19 waves.Microbiology spectrum · 2025Article
- Outcomes of Fecal Microbiota Transplantation forOpen forum infectious diseases · 2025Article
- Gut microbiome and lung cancer: mechanisms, interactions, and dietary interventions.Gut microbes reports · 2025Review
- Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.Frontiers in microbiology · 2025Review
- 3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.The EPMA journal · 2024Article
- Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.Medical oncology (Northwood, London, England) · 2024Review
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- Article
- The impact of antibiotic exposure on antibiotic resistance gene dynamics in the gut microbiota of inflammatory bowel disease patients.Frontiers in microbiology · 2024Article
- Colonic transendoscopic enteral tubing is revolutionizing intestinal therapeutics, diagnosis, and microbiome research.Therapeutic advances in gastroenterology · 2024Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 16 institutions in 12 countries.
Gianluca IaniroDigestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0002-8318-0515
Benjamin H MullishDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.ORCID 0000-0001-6300-3100
Colleen R KellyDivision of Gastroenterology, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Zain KassamFinch Therapeutics Group, Somerville, Massachusetts, USA.
Ed J KuijperCenter for Microbiota Analysis and Therapy, Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.
Siew C NgCenter for Gut Microbiota Research, Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong.ORCID 0000-0002-6850-4454
Tariq H IqbalMicrobiome Treatment Centre, University of Birmingham, Birmingham, UK.
Jessica R AllegrettiGastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Stefano BibbòDigestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Harry SokolService de Gastroenterologie; French Group of Fecal Microbiota Transplantation, Hôpital Saint Antoine, Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France.
Faming ZhangMedical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Monika FischerDepartment of Medicine, Indiana University, Indianapolis, Indiana, USA.
Samuel Paul CostelloDepartment of Gastroenterology, The Queen Elizabeth Hospital, University of Adelaide, Woodville, South Australia, Australia.
Josbert J KellerNetherlands Donor Feces Bank, Leiden University Medical Center, Leiden, The Netherlands.
Luca MasucciInstitute of Microbiology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
Joffrey van PrehnNetherlands Donor Feces Bank, Leiden University Medical Center, Leiden, The Netherlands.
Gianluca QuarantaInstitute of Microbiology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
Mohammed Nabil QuraishiMicrobiome Treatment Centre, University of Birmingham, Birmingham, UK.ORCID 0000-0003-2338-8397
Jonathan SegalDepartment of Gastroenterology, St Mark's Hospital, Harrow, UK.ORCID 0000-0002-9668-0316
Dina KaoDivision of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Reetta SatokariHuman Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Maurizio SanguinettiInstitute of Microbiology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
Herbert TilgDepartment of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Innsbruck Medical University, Innsbruck, Austria.ORCID 0000-0002-4235-2579
Antonio GasbarriniDigestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Giovanni CammarotaDigestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy giovanni.cammarota@unicatt.it.ORCID 0000-0002-3626-6148
Università Cattolica del Sacro Cuore · ITLeiden University Medical Center · NLUniversity Hospitals Birmingham NHS Foundation Trust · GBBrigham and Women's Hospital · USBrown University · USChinese University of Hong Kong · HKFinch Therapeutics (United States) · USImperial College London · GBIndiana University – Purdue University Indianapolis · USInnsbruck Medical University · ATInserm · FRQueen Elizabeth Hospital · AUSecond Affiliated Hospital of Nanjing Medical University · CNSt Mark's Hospital · GBUniversity of Alberta · CAUniversity of Helsinki · FI
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of
Indexed as
Coronavirus InfectionsDonor SelectionGastroenterologyPandemicsPatient SelectionPneumonia, ViralBetacoronavirusChange ManagementClostridium InfectionsCOVID-19Fecal Microbiota TransplantationGastrointestinal MicrobiomeHumansInfection ControlRisk AdjustmentSARS-CoV-2colonic microfloradiarrhoeal disease
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT04759001ClinicalTrials.gov
NCT06992453ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.